Novo Nordisk and Eli Lilly currently control 99% of the market, but their dominance may weaken as new entrants introduce ...

Hims & Hers Health (HIMS) has disclosed plans to shut down Apostrophe, its acne treatment business. This change is part of ...

How to eat well with diabetes – and save money doing it - Miguel Barclay has built a reputation on proving that good food ...

Blackstone, BlackRock, and Novo Nordisk A/S are the three Growth stocks to watch today, according to MarketBeat’s stock screener tool. Growth stocks are shares of companies that are expected to grow ...

Blackstone, BlackRock, Apollo Global Management, Novo Nordisk A/S, Welltower, Prologis, and Venture Global are the seven Growth stocks to watch today, according to MarketBeat’s stock screener tool.

Hims & Hers Health will shut down Apostrophe, its personalized acne treatments dermatology business, the company said on Friday. Apostrophe is being shut down to “simplify its (company’s) dermatology ...

The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...

(Reuters) -Hims & Hers Health would discontinue Apostrophe, its personalized acne treatments dermatology business, the ...

Insurance companies generally cover Ozempic and Wegovy when it is prescribed for Type-2 diabetes. However, when the drugs are ...

With semaglutide shortages in the rearview, Novo Nordisk is doubling down on marketing efforts for its GLP-1 drugs.

A U.S. federal judge has refused to allow compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss and ...

The makers of two popular weight-loss drugs — Wegovy and Zepbound — are cutting prices to make the medications more af ...